|Bid||95.060 x 300|
|Ask||95.080 x 400|
|Day's Range||93.695 - 95.290|
|52 Week Range||79.120 - 112.970|
|PE Ratio (TTM)||19.16|
|Earnings Date||Oct 18, 2017 - Oct 23, 2017|
|Dividend & Yield||1.80 (1.95%)|
|1y Target Est||99.13|
Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.
Quest Diagnostics Inc. said on Thursday that despite greater-than-expected proposed cuts to Medicare reimbursement for lab tests, the company should still meet the guidance it has set for coming years. ...
Considering hurricanes related financial impact and recently-closed acquisitions, Quest Diagnostics' (DGX) management has revised its guidance for full year 2017.
- Third quarter revenues of $1.93 billion , up 2.4% versus 2016. - Third quarter reported diluted EPS of $1.15 , down 14.2% from 2016, which included an acquisition escrow recovery gain; and $1.39 on an ...
NEW YORK, NY / ACCESSWIRE / October 19, 2017 / Quest Diagnostics Incorporated (NYSE: DGX ) will be discussing their earnings results in their Q3 Earnings Call to be held on October 19, 2017 at 8:30 AM ...
SECAUCUS, N.J. and CLEVELAND, Oct. 18, 2017 /PRNewswire/ -- Quest Diagnostics (DGX) today announced it has formed a definitive agreement to acquire Cleveland HeartLab, a leader in innovative diagnostic services for managing cardiovascular disease, from equity investors, including Cleveland Clinic. Quest intends to establish a national center of excellence in diagnostic information services at Cleveland HeartLab's specialized laboratory in Cleveland, Ohio, focused on services that aid in assessing risk and treatment protocols for heart disease, the leading cause of death in the United States.
The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.
Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.
After the completion of Shiel's acquisition, the medical lab is expected to expand Quest Diagnostics' (DGX) physician and patient service centers network in the New York-New Jersey area.
SECAUCUS, N.J. and HARTFORD, Conn., Sept. 29, 2017 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced it has acquired the outreach lab services operations of two hospitals of Hartford HealthCare (HHC), The William W. Backus Hospital and The Hospital of Central Connecticut. HHC is an integrated health care system with five acute care hospitals in Connecticut.